Oncolytics Biotech Inc T.ONC

Q for notable

[westcoast1000]

If someone like Roche licenses (or buys) Pncy and pela, should I presume they would also get the extended patent protection for a combo treatment of pela with their panc treatment?

[Noteable]

With repect to pelareorep + atezolizumab (Tecentriq) in pancreatic cancer, if Roche were to license pelareorep or to obtain outright possession of pelareorep through the acquisition of ONCY, and were to then seek and obtain CBER marketing approval for this biologic-drug/biologic combination, Roche would gain 12 years of FDA market exclusivity for this "biologic-led" combinational product

[Noteable]

I should point out that the specificity of each agent in the pelareorep + atezolizumab combination gives this combination exclusivity by its very nature. This notwithstanding ONCY's patent on pelareorep is extendable until 2033, thus effectively providing patent protection for another 11 years.

[Noteable]

I would also think that in this example of pelareorep + atezolizumab in pancreatic cancer, once this combination is given marketing approval, pelareorep alone would be granted an automatic 12 years of FDA market exclusivity from the date of approval in this indication, since it is a biologic, and separate from atezolizumab. So the benefit here would not only be this combination's

[westcoast1000]

Thanks, Notalbe. That factor alone should clearly contribute substantially to a buy-out or partnership price. They could greatly extend their patent protection for Tecentriq, and improve its efficacy, and expand their market, assuming the ongoing trial works similarly to the first one.